`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
`
` NDA 202895/S-4
`
` NDA 21976/S-27
`
`
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
` Janssen Products, L.P.
`
` Attention: Karen Gerry, BSc.
`
`
` Manager, Global Regulatory Affairs
` 1125 Trenton-Harbourton Rd
`
`
` Titusville, NJ 08560
`
`
`
`
`
`Dear Ms. Gerry:
`
`
`
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Applications (sNDA) dated and received July 2,
`
`
`
`
`2012 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for
`Prezista® (darunavir) tablets, 75 mg, 150 mg, 400 mg, 600 mg, and 800 mg, and Prezista®
`
`
` (darunavir) oral suspension, 100 mg/mL.
`
`
` We acknowledge receipt of your amendments dated September 27, 2012, October 4, 2012,
`
`
`
`
` November 02, 2012, November 7, 2012, November 27, 2012, December 14, 2012, March 8,
` 2012, and April 4, 2013.
`
`
` These “Prior Approval” supplemental new drug applications propose to update labeling with 48
`
`
`
`
`
`
`
` week pharmacokinetic, safety, tolerability, and virologic response data for HIV-1 treatment-
`
`
`
`
` experienced pediatric patients three to less than six years of age.
`
` We have completed our review of these supplemental applications, as amended. They are
`
`
`
`
`
` approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-
`
` upon labeling text.
`
` CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`
`
`
`
`
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`
`automated drug registration and listing system (eLIST), as described at
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`
`of labeling must be identical to the enclosed labeling (text for the package insert, patient package
`
`
`
`insert ), with the addition of any labeling changes in pending “Changes Being Effected” (CBE)
`
`supplements, as well as annual reportable changes not included in the enclosed labeling.
`
`
`
`
`Reference ID: 3298512
`
`
`
`
`
`
`
`
`
`
` NDA 202895/S-4
`
` NDA 21976/S-27
`
` Page 2
`
`
`
`
` Information on submitting SPL files using eList may be found in the guidance for industry titled
` “SPL Standard for Content of Labeling Technical Qs and As at
`
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf
`
`
` The SPL will be accessible from publicly available labeling repositories.
`
`
`
`
`
`Also within 14 days, amend all pending supplemental applications that includes labeling changes
`
`
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`
`
`
`
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`
`changes approved in this supplemental application, as well as annual reportable changes and
`
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`
`
`should provide appropriate annotations, including supplement number(s) and annual report
`
`date(s).
`
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`
`
`active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
`
`
`
`administration are required to contain an assessment of the safety and effectiveness of the
`
`
`product for the claimed indication(s) in pediatric patients unless this requirement is waived,
`
`
`deferred, or inapplicable.
`
`
`Because none of these criteria apply to your application, you are exempt from this requirement.
`
`
`
`PROMOTIONAL MATERIALS
`
`
`You may request advisory comments on proposed introductory advertising and promotional
`
`
`
`
`
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`
`
`
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`
`(3) the package insert(s) to:
`
`
`
`Food and Drug Administration
`
`Center for Drug Evaluation and Research
`
`Office of Prescription Drug Promotion (OPDP)
`
`5901-B Ammendale Road
`
`Beltsville, MD 20705-1266
`
`
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`
`
`
`
`
`FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html;
`
`instructions are provided on page 2 of the form. For more information about submission of
`
`
`promotional materials to the Office of Prescription Drug Promotion (OPDP), see
`
`http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`
`Reference ID: 3298512
`
`
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`
`Debra Birnkrant, MD
`
`Director
`
`Division of Antiviral Products
`
`Office of Antimicrobial Products
`
`Center for Drug Evaluation and Research
`
`
` NDA 202895/S-4
`
` NDA 21976/S-27
`
` Page 3
`
`
` REPORTING REQUIREMENTS
`
` We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
` (21 CFR 314.80 and 314.81).
`
`
`
`
`
`
`
`If you have any questions, call Linda C. Onaga, MPH, Regulatory Project Manager, at (301)
`
`796-0759 or (301) 796-1500.
`
`
`
`
`
`
`
`ENCLOSURE(S):
`
`
`Content of Labeling
`
`Reference ID: 3298512
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`JEFFREY S MURRAY
`04/24/2013
`
`Reference ID: 3298512
`
`